|
USA-MA-BRIGHTON Azienda Directories
|
Azienda News:
- FDA expands approval of Modernas RSV vaccine to some adults under age . . .
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease
- Moderna Receives U. S. FDA Approval for RSV Vaccine, mRESVIA, in Adults . . .
Expanded indication builds on existing U S FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA ACCESS Newswire June 12, 2025 Moderna, Inc (NASDAQ:MRNA) today announced that the U S Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD
- FDA expands approval for Modernas RSV vaccine - The Hill
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from
- Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger . . .
The US Food and Drug Administration (FDA) has expanded approval of Moderna’s respiratory syncytial virus (RSV) vaccine to include younger adults at risk, though its still uncertain whether the shot will be recommended for broader use in the national immunisation schedule Moderna’s vaccine, known under the brand name mRESVIA, became the first non-Covid-19 messenger RNA-based (mRNA) vaccine
- FDA approves Moderna RSV vaccine use for people aged 18 to 59 - STAT
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win
- FDA Expands Moderna’s mRNA-1345 RSV Vaccine to Younger Adults
The FDA has expanded the approval of Moderna’s mRNA-1345 RSV vaccine to include people aged 18-59 years This comes after last year’s initial approval of the vaccine for seniors 60 years of age and older in prevention of lower respiratory tract disease caused by RSV infection 1 "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an
- FDA expands Modernas RSV vaccine approval to at-risk adults - MSN
The U S Food and Drug Administration has approved Moderna’s (NASDAQ:MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 who are at
- Moderna wins FDA OK to widen use of RSV vaccine
The Food and Drug Administration has approved wider use of Moderna’s respiratory syncytial virus vaccine in a boost for a company that’s been negatively impacted by the recent leadership changes atop U S public health agencies The shot, dubbed mResvia, was cleared on Thursday for adults aged 18 to 59 who are at high risk for increased risk of RSV-related disease Prior to the label
- FDA Approves Moderna’s RSV Vaccine for Younger Adults
US regulators approved Moderna Inc ’s vaccine to prevent a common respiratory illness for more adults, a potential easing of the Trump administration’s opposition to mRNA technology
- Moderna receives FDA approval for RSV vaccine mRESVIA for at-risk . . .
Moderna Receives U S FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease June 12, 2025
|
|